LDN Social Media
Get connected with us on social networks
Psychopharmacologic Therapies for Irritable Bowel Syndrome (Abstract)
Gastroenterol Clin North Am
Epub 01 July 2021
https://pubmed.ncbi.nlm.nih.gov/34304793/
Psychopharmacologic therapies are beneficial in reducing symptoms when treating irritable bowel syndrome (IBS) and other disorders of gut-brain interaction (DGBI). Noradrenaline, serotonin, and dopamine are neurotransmitters of key importance in psychopharmacology and pain-reduction mechanisms. The first-line (tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors, selective serotonin reuptake inhibitors) and second-line (atypical antipsychotics, delta-ligand agents, low-dose naltrexone) neuromodulator treatment options are recommended when IBS-associated abdominal pain is of moderate or severe intensity and is persistent. To understand the implementation strategy, the multidimensional clinical profile as a template is used for presenting 3 case scenarios involving painful IBS and DGBI of varying complexity.
Keywords: Antidepressants; Disorders of gut brain interaction; Irritable bowel syndrome; Multidimensional clinical profile; Neuromodulator; Treatment.